Published on February 25, 2010 at 3:23 AM
“The submission of KW-2246 in Japan is an important step in
the international development of Orexo’s sublingual fentanyl product, in
Europe launched under the brand AbstralTM. The success of Abstral is
confirmed by its strong sales growth in Europe.”
Orexo AB (STO:ORX) today announces that its partner Kyowa Hakko Kirin
Co., Ltd. has submitted the New Drug Application (NDA) in Japan for the
cancer pain drug KW-2246 (Abstral).
Kyowa Hakko Kirin has confirmed KW-2246’s safety and efficacy in
clinical trials conducted in Japan.
The drug will be marketed by Kyowa Hakko Kirin and Hisamitsu
Pharmaceutical Co., Inc. Kyowa Hakko Kirin and Hisamitsu will also
market HFT-290 (Fentanyl transdermal patch) under development by
Hisamitsu.
Commenting on the announcement, Torbjörn Bjerke, Orexo’s President and
CEO, said: “The submission of KW-2246 in Japan is an important step in
the international development of Orexo’s sublingual fentanyl product, in
Europe launched under the brand AbstralTM. The success of Abstral is
confirmed by its strong sales growth in Europe.
This submission further strengthens that Orexos sublingual fentanyl
product has the potential to be an important product for the treatment
of severe pain episodes in cancer patients globally. The submission is a
result of the continued strong commitment we see from our partner Kyowa
Hakko Kirin in the Japanese market.”
SOURCE Orexo AB